Bekawi Mohammad S, El Wakeel Lamia M, Al Taher Waleed M A, Mageed Walid M A
*Department of Clinical Pharmacy, Faculty of Pharmacy †Department of Anesthesia And Intensive Care, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Clin J Pain. 2014 Nov;30(11):944-52. doi: 10.1097/AJP.0000000000000060.
To evaluate the efficacy and tolerability of pregabalin in postoperative pain management after laparoscopic cholecystectomy (LC).
A prospective, randomized, placebo, controlled, double-blinded study was conducted at Anesthesia Department, Laparoscopy Surgery Unit, Ain Shams University Hospital. Ninety patients with ASA physical status I-II scheduled for elective LC under general anesthesia were included. Patients were randomly assigned to the following groups (n=30 each): pregabalin group (P), received 150 mg pregabalin capsules 2 hours preoperatively, 12 hours postoperatively, and twice daily for 2 days; gabapentin group (G), received 1200 mg gabapentin capsules (400 mg, ×3) 2 hours preoperatively, 12 hours postoperatively, and 400 mg three times daily for 2 days; and control group (C), received placebo capsules. Postoperative pain scores were recorded on a visual analogue scale. The following data were recorded: total daily pethidine and diclofenac consumption, numeric sedation score, and the postoperative nausea, vomiting, and dizziness scores.
The 24-hour pethidine consumption was significantly lower (P<0.001) in both pregabalin and gabapentin groups versus control. Both groups had significantly less (P<0.001) patients with postoperative nausea, vomiting, sedation, and dizziness versus control. Overall patient satisfaction with pain management was significantly higher (P<0.001) in pregabalin group versus gabapentin or control groups.
Gabapentin 1200 mg and pregabalin 150 mg are effective and safe analgesics for reducing postoperative pain in LC. The perioperative oral administration of pregabalin 150 mg in patients undergoing LC is an effective and safe method of analgesia with a low incidence of adverse effects and reduces postoperative pethidine consumption.
评估普瑞巴林在腹腔镜胆囊切除术（LC）术后疼痛管理中的疗效和耐受性。
在艾因夏姆斯大学医院腹腔镜外科麻醉科进行了一项前瞻性、随机、安慰剂对照、双盲研究。纳入90例拟在全身麻醉下行择期LC的ASA身体状况I-II级患者。患者被随机分为以下几组（每组n = 30）：普瑞巴林组（P），术前2小时、术后12小时服用150 mg普瑞巴林胶囊，每日2次，共2天；加巴喷丁组（G），术前2小时、术后12小时服用1200 mg加巴喷丁胶囊（400 mg，×3），术后每日3次，每次400 mg，共2天；对照组（C），服用安慰剂胶囊。采用视觉模拟评分法记录术后疼痛评分。记录以下数据：每日哌替啶和双氯芬酸总消耗量、数字镇静评分以及术后恶心、呕吐和头晕评分。
普瑞巴林组和加巴喷丁组24小时哌替啶消耗量均显著低于对照组（P<0.001）。与对照组相比，两组术后恶心、呕吐、镇静和头晕的患者均显著减少（P<0.001）。普瑞巴林组患者对疼痛管理的总体满意度显著高于加巴喷丁组或对照组（P<0.001）。
1200 mg加巴喷丁和150 mg普瑞巴林是减轻LC术后疼痛的有效且安全的镇痛药。LC患者围手术期口服150 mg普瑞巴林是一种有效且安全的镇痛方法，不良反应发生率低，并可减少术后哌替啶消耗量。
